An Entity of Type: Thing, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Omega-3 carboxylic acids (Epanova) is a formerly-marketed yet still FDA approved prescription medication–since taken off market by the manufacturer–used alongside a low fat and low cholesterol diet that lowers high triglyceride (fat) levels in adults with very high levels. This was the third class of fish oil-based drug, after omega-3 acid ethyl esters (Lovaza and Omtryg) and ethyl eicosapentaenoic acid (Vascepa), to be approved for use as a drug. The first approval by US Food and Drug Administration was granted 05 May 2014. These fish oil drugs are similar to fish oil dietary supplements, but the ingredients are better controlled and have been tested in clinical trials. Specifically, Epanova contained at least 850 mg omega-3-acid ethyl esters per 1 g capsule.

Property Value
dbo:abstract
  • Omega-3 carboxylic acids (Epanova) is a formerly-marketed yet still FDA approved prescription medication–since taken off market by the manufacturer–used alongside a low fat and low cholesterol diet that lowers high triglyceride (fat) levels in adults with very high levels. This was the third class of fish oil-based drug, after omega-3 acid ethyl esters (Lovaza and Omtryg) and ethyl eicosapentaenoic acid (Vascepa), to be approved for use as a drug. The first approval by US Food and Drug Administration was granted 05 May 2014. These fish oil drugs are similar to fish oil dietary supplements, but the ingredients are better controlled and have been tested in clinical trials. Specifically, Epanova contained at least 850 mg omega-3-acid ethyl esters per 1 g capsule. Following phase III clinical trial in mixed dyslipidaemia, AstraZeneca announced on 13 January 2019 that their clinical trials were terminated for futility because no medical benefit of the medication could be found. (en)
  • Ácidos carboxílicos ômega-3 (Epanova) é um medicamento de prescrição, anteriormente comercializado mas ainda aprovado pela Administração de alimentos e medicamentos (FDA) (desde que retirado do mercado pelo fabricante), usado juntamente com uma dieta com baixo teor de gordura e colesterol que reduz os níveis elevados de triglicerídeos (gordura) em adultos com níveis muito altos. Esta foi a terceira classe de medicamento à base de óleo de peixe, depois dos ésteres etílicos de ácido ômega-3 (Lovaza e Omtryg) e do ácido etil eicosapentaenóico (Vascepa), a ser aprovada para uso como medicamento. A primeira aprovação pela Administração de alimentos e medicamentos (FDA) dos E.U.A. foi concedida em 05 de maio de 2014. Esses medicamentos de óleo de peixe são semelhantes aos suplementos dietéticos de óleo de peixe, mas os ingredientes são melhor controlados e foram testados em ensaios clínicos. Especificamente, o Epanova continha pelo menos 850 mg de ésteres etílicos de ácidos ômega-3 por cápsula de 1 g. Após o ensaio clínico de fase III em dislipidemia mista, a AstraZeneca anunciou em 13 de janeiro de 2019 que seus ensaios clínicos foram encerrados por inutilidade porque nenhum benefício médico do medicamento foi encontrado. (pt)
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 44853585 (xsd:integer)
dbo:wikiPageLength
  • 14140 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1097011961 (xsd:integer)
dbo:wikiPageWikiLink
dbp:wikiPageUsesTemplate
dcterms:subject
rdfs:comment
  • Omega-3 carboxylic acids (Epanova) is a formerly-marketed yet still FDA approved prescription medication–since taken off market by the manufacturer–used alongside a low fat and low cholesterol diet that lowers high triglyceride (fat) levels in adults with very high levels. This was the third class of fish oil-based drug, after omega-3 acid ethyl esters (Lovaza and Omtryg) and ethyl eicosapentaenoic acid (Vascepa), to be approved for use as a drug. The first approval by US Food and Drug Administration was granted 05 May 2014. These fish oil drugs are similar to fish oil dietary supplements, but the ingredients are better controlled and have been tested in clinical trials. Specifically, Epanova contained at least 850 mg omega-3-acid ethyl esters per 1 g capsule. (en)
  • Ácidos carboxílicos ômega-3 (Epanova) é um medicamento de prescrição, anteriormente comercializado mas ainda aprovado pela Administração de alimentos e medicamentos (FDA) (desde que retirado do mercado pelo fabricante), usado juntamente com uma dieta com baixo teor de gordura e colesterol que reduz os níveis elevados de triglicerídeos (gordura) em adultos com níveis muito altos. Esta foi a terceira classe de medicamento à base de óleo de peixe, depois dos ésteres etílicos de ácido ômega-3 (Lovaza e Omtryg) e do ácido etil eicosapentaenóico (Vascepa), a ser aprovada para uso como medicamento. A primeira aprovação pela Administração de alimentos e medicamentos (FDA) dos E.U.A. foi concedida em 05 de maio de 2014. Esses medicamentos de óleo de peixe são semelhantes aos suplementos dietéticos (pt)
rdfs:label
  • Omega-3 carboxylic acids (en)
  • Ácidos carboxílicos ômega-3 (pt)
owl:sameAs
prov:wasDerivedFrom
foaf:homepage
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License